AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23895180 — intervention group
Group type: COMPARATOR
Intervention: Gastric electrical stimulation (GES) OFF
Number of subjects: 32
Study 21439633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (loading dose 1 g over 10 min followed by infusion of 1 g over 8 h)
Number of subjects: 20111
Study 21439633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20111
Study 17998903 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-deficit
Number of subjects: 13
Study 17998903 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-replacement
Number of subjects: 13
Study 17998903 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study 17164546 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 70
Study 17164546 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 70
Study 12918131 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 2 (saccharomyces boulardii 250 mg Tid + metronidazole 750 mg Tid + iodoquinol 630 mg Tid for 10 days)
Number of subjects: 54
Study 12918131 — intervention group
Group type: COMPARATOR
Intervention: Regimen 1 (metronidazole 750 mg Tid + iodoquinol 630 mg Tid for 10 days)
Number of subjects: 54
Study 10889424 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof 5.5 mm
Number of subjects: 302
Study 10889424 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof 6.0 mm
Number of subjects: 302
Study 10889424 — intervention group
Group type: EXPERIMENTAL
Intervention: SI-40
Number of subjects: 302
Study 10889424 — intervention group
Group type: COMPARATOR
Intervention: Control group (presbyopia only)
Number of subjects: 302
Study 10889424 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 302
Study 9127654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 107
Study 9127654 — intervention group
Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 107
Study 9127654 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 107
Study 8413982 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory cerebral events related to the most frequently occurring stimulus; measured by premovement potentials.
Number of subjects: 0
Study 8413982 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to the least probable stimulus; measured by accuracy and speed of response.
Number of subjects: 0
Study 8413982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral potentials measured by scalp distribution after unexpected stimulus occurrence.
Number of subjects: 0
Study 29348010 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolut PRO valve
Number of subjects: 60
Study 27172483 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 0
Study 27172483 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 25436769 — intervention group
Group type: EXPERIMENTAL
Intervention: IV 1-2×10(6) bone-marrow-derived MSCs/Kg
Number of subjects: 9
Study 25436769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 21959100 — intervention group
Group type: EXPERIMENTAL
Intervention: Lively Legs program
Number of subjects: 184
Study 21959100 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 184
Study 19659665 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol mouth rinse (1 mg/ml)
Number of subjects: 33
Study 19659665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 18570643 — intervention group
Group type: EXPERIMENTAL
Intervention: Family assisted exercises
Number of subjects: 40
Study 18570643 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 40
Study 16005976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp-edged IOL (Sensar AR40e)
Number of subjects: 75
Study 16005976 — intervention group
Group type: COMPARATOR
Intervention: Rounded-edge IOL (Sensar AR40)
Number of subjects: 75
Study 12454616 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus information leaflet
Number of subjects: 124
Study 12454616 — intervention group
Group type: COMPARATOR
Intervention: Information leaflet alone
Number of subjects: 124
Study 10604042 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba extract EGb 761 120 mg/d
Number of subjects: 74
Study 10604042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 240 mg/d
Number of subjects: 74
Study 8770319 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg once daily for 6 weeks)
Number of subjects: 26
Study 8770319 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg once daily for 6 weeks)
Number of subjects: 26
Study 8770319 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 26
Study 8770319 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 26
Study 1682226 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg D,L-kawain
Number of subjects: 0
Study 1682226 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg D,L-kawain
Number of subjects: 0
Study 1682226 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg D,L-kawain
Number of subjects: 0
Study 1682226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7137521 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms daily)
Number of subjects: 0
Study 7137521 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (100 micrograms daily)
Number of subjects: 0
Study 7137521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31594892 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving incidental results from genomic sequencing
Number of subjects: 260
Study 31594892 — intervention group
Group type: COMPARATOR
Intervention: Not receiving incidental results from genomic sequencing
Number of subjects: 260
Study 30245281 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC 975/292.5
Number of subjects: 408
Study 30245281 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 975 mg
Number of subjects: 408
Study 30245281 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 292.5 mg
Number of subjects: 408
Study 30245281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 30245281 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 408
Study 26916487 — intervention group
Group type: EXPERIMENTAL
Intervention: Public reporting of hospital readmission rates (CMS implementation)
Number of subjects: 217094
Study 25230866 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour extended infusion of meropenem (1 g dissolved in 40 mL saline, followed by 750 mg continuous infusion for 3 hours, repeated every 8 hours)
Number of subjects: 78
Study 25230866 — intervention group
Group type: COMPARATOR
Intervention: 30-minute infusion of meropenem (1 g dissolved in 40 mL saline, intravenous infusion within 30 minutes every 8 hours)
Number of subjects: 78
Study 25230866 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour extended infusion of meropenem
Number of subjects: 78
Study 25230866 — intervention group
Group type: COMPARATOR
Intervention: 30-minute infusion of meropenem
Number of subjects: 78
Study 22391671 — intervention group
Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip tube
Number of subjects: 40
Study 22391671 — intervention group
Group type: COMPARATOR
Intervention: Standard tube
Number of subjects: 40
Study 20002472 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance tests (OGTT)
Number of subjects: 887
Study 20002472 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated impaired glucose tolerance
Number of subjects: 887
Study 20002472 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated impaired fasting glucose
Number of subjects: 887
Study 20002472 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, parental diabetes, body mass index, uric acid, current smoking, HbA(1c), fasting and 2-h glucose (OGTT)
Number of subjects: 887
Study 17480223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 105
Study 17480223 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (No-MBP)
Number of subjects: 105
Study 17480223 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MBP and No-MBP)
Number of subjects: 105
Study 14997083 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.01 microg/kg/min) with propofol (site‐effect 3.0 microg/ml)
Number of subjects: 60
Study 14997083 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.1 microg/kg/min) with propofol (site‐effect 3.0 microg/ml)
Number of subjects: 60
Study 14997083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (sufentanil and remifentanil)
Number of subjects: 60
Study 11642080 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once a day)
Number of subjects: 31
Study 11642080 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120-180 mg twice a day)
Number of subjects: 31
Study 9724072 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg EE2 combined with 75 microg gestodene (EE2/GSD)
Number of subjects: 47
Study 9724072 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg EE2 combined with 150 microg desogestrel (EE2/DES)
Number of subjects: 47
Study 8030850 — intervention group
Group type: EXPERIMENTAL
Intervention: Antagonic-Stress (AS) composition
Number of subjects: 62
Study 8030850 — intervention group
Group type: COMPARATOR
Intervention: Nicergoline (NE)
Number of subjects: 62
Study 2480576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1000 mg/kg
Number of subjects: 21
Study 2480576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 750 mg/kg
Number of subjects: 21
Study 2480576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 500 mg/kg
Number of subjects: 21
Study 31177406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluence Q-switched Nd:YAG 1064-nm laser (LFQS 1064-nm)
Number of subjects: 30
Study 31177406 — intervention group
Group type: COMPARATOR
Intervention: Q-switched Nd:YAG 532-nm laser (QS 532-nm)
Number of subjects: 30
Study 30508090 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatments + brexpiprazole
Number of subjects: 2066
Study 30508090 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant treatments + placebo
Number of subjects: 2066
Study 28329859 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing training
Number of subjects: 2390
Study 28329859 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 2390
Study 28329859 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing training with booster sessions
Number of subjects: 2390
Study 28329859 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 2390
Study 28329859 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 2390
Study 25660106 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with 5 methyl‐aminolevulinate
Number of subjects: 13
Study 25660106 — intervention group
Group type: COMPARATOR
Intervention: Trichloroacetic acid 50%
Number of subjects: 13
Study 24802654 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin (GC)
Number of subjects: 88
Study 24802654 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin with cetuximab (GC + CTX)
Number of subjects: 88
Study 22968058 — intervention group
Group type: EXPERIMENTAL
Intervention: cutaneous lysate skin cream applied twice daily for 3 months
Number of subjects: 30
Study 19296743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (plant-based diet)
Number of subjects: 2254
Study 19296743 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 2254
Study 17961086 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0
Study 15871655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoeconomic modeling
Number of subjects: 0
Study 15871655 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapies
Number of subjects: 0
Study 15871655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effective therapy
Number of subjects: 0
Study 15871655 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial results
Number of subjects: 0
Study 12134984 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival rotation autograft (Group A)
Number of subjects: 31
Study 12134984 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival autograft (Group B)
Number of subjects: 31
Study 9792296 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin
Number of subjects: 1897
Study 7890059 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 (50 mg daily for 6 months)
Number of subjects: 18
Study 7890059 — intervention group
Group type: COMPARATOR
Intervention: Control (normal cycling women in the follicular phase)
Number of subjects: 18
Study 2098016 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with insect venom
Number of subjects: 242
Study 2098016 — intervention group
Group type: COMPARATOR
Intervention: Control (no immunotherapy)
Number of subjects: 242
Study 491472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 1% combined with 0.05% dipivalyl-epinephrine
Number of subjects: 2
Study 491472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 1% combined with 0.1% dipivalyl-epinephrine
Number of subjects: 2
Study 491472 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine 1%
Number of subjects: 2
Study 31520215 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking at 0.89 m/s for 4 minutes
Number of subjects: 29
Study 28439893 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-induction therapy (including fludarabine, cytarabine ± anthracyclines)
Number of subjects: 543
Study 28439893 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) as consolidation therapy after relapse
Number of subjects: 543
Study 28439893 — intervention group
Group type: COMPARATOR
Intervention: No SCT as part of relapse therapy
Number of subjects: 543
Study 28439893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive re-induction followed by SCT
Number of subjects: 543
Study 26022214 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially defatted Granulated Brazil nut (GBN) 13 g per day (≈227.5 μg/day of selenium)
Number of subjects: 91
Study 23972450 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 23972450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21606391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 13420
Study 21606391 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious bleeding events
Number of subjects: 13420
Study 19404724 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive behavioral therapy (CBT)
Number of subjects: 67
Study 19404724 — intervention group
Group type: COMPARATOR
Intervention: Support strategy
Number of subjects: 67
Study 16778713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicloral (CIC)
Number of subjects: 12
Study 16778713 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (NEO)
Number of subjects: 12
Study 16778713 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune (SIM)
Number of subjects: 12
Study 16778713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cmax for Cicloral (CIC)
Number of subjects: 12
Study 16778713 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary recovery of CyA
Number of subjects: 12
Study 16778713 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐demethylated metabolite AM4N
Number of subjects: 12
Study 15308881 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitor therapy
Number of subjects: 635
Study 15308881 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure treatment strategy achieving 128/78 mm Hg (low blood pressure goal)
Number of subjects: 635
Study 15308881 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment through screening in clinical practice
Number of subjects: 635
Study 10401453 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-free period (4 weeks)
Number of subjects: 31
Study 7674179 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (no surface treatment)
Number of subjects: 15
Study 7674179 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (saliva-contaminated)
Number of subjects: 15
Study 2213868 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk sexual behavior index
Number of subjects: 0
Study 2213868 — intervention group
Group type: EXPERIMENTAL
Intervention: Social context variables (family structure, parenting practices, friends' engagement in problem behaviors)
Number of subjects: 0
Study 2213868 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem behaviors and social context variables
Number of subjects: 0
Study 7406949 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (4 X 250 mg per day for 4 months)
Number of subjects: 27
Study 7406949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31504694 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin A (VA)
Number of subjects: 306
Study 31504694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 306
Study 30296404 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychromatic blue-enriched light (17,000 K)
Number of subjects: 20
Study 30296404 — intervention group
Group type: COMPARATOR
Intervention: Standard white polychromatic light (4000 K)
Number of subjects: 20
Study 28432376 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg MDMA
Number of subjects: 39
Study 28432376 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg MDMA
Number of subjects: 39
Study 28432376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 25132461 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 3% topical gel
Number of subjects: 360
Study 25132461 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 360
Study 22782343 — intervention group
Group type: EXPERIMENTAL
Intervention: Huachansu plus gemcitabine (gemcitabine 1000 mg m(‐2) on days 1, 8, and 15 with huachansu 20 ml m(‐2) daily for 21 days)
Number of subjects: 80
Study 22782343 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine (gemcitabine 1000 mg m(‐2) on days 1, 8, and 15 with placebo)
Number of subjects: 80
Study 20437680 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Number of subjects: 180
Study 20437680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 17984856 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsants
Number of subjects: 0
Study 17984856 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 0
Study 16319406 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 263
Study 16319406 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 263
Study 12071241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway
Number of subjects: 100
Study 12071241 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 100
Study 10548627 — intervention group
Group type: EXPERIMENTAL
Intervention: recFSH supplemented medium
Number of subjects: 143
Study 10548627 — intervention group
Group type: COMPARATOR
Intervention: simple medium
Number of subjects: 143
Study 8847279 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2
Number of subjects: 12
Study 1973879 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine 140 mg/day (Group I)
Number of subjects: 24
Study 1973879 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine 270 mg/day (Group II)
Number of subjects: 24
Study 6273551 — intervention group
Group type: EXPERIMENTAL
Intervention: Otosporin (antibiotic/steroid ear drops)
Number of subjects: 126
Study 6273551 — intervention group
Group type: COMPARATOR
Intervention: Aluminium acetate ear drops
Number of subjects: 126
Study 30425095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsevere hypoglycemia
Number of subjects: 11495
Study 30425095 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia
Number of subjects: 11495
Study 27395330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional treatment + synbiotic (Lactobacillus and Bifidobacterium strains + 6 g fructooligosaccharides)
Number of subjects: 64
Study 27395330 — intervention group
Group type: COMPARATOR
Intervention: Nutritional treatment + placebo (6 g maltodextrin)
Number of subjects: 64
Study 26244563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional botulinum toxin A (5 U per 1 cm2)
Number of subjects: 18
Study 26244563 — intervention group
Group type: COMPARATOR
Intervention: Intralesional saline placebo
Number of subjects: 18
Study 24862330 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 or 250 mg/d for 2 weeks
Number of subjects: 19
Study 24862330 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 375, 625, 750, and 875 mg with exposure enhancement (EE)
Number of subjects: 19
Study 24862330 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant doses of 875 mg (625 mg with EE) or higher
Number of subjects: 19
Study 24862330 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 19
Study 21094553 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI diet
Number of subjects: 47
Study 21094553 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 47
Study 19462434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor M2-PK
Number of subjects: 199
Study 19462434 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin
Number of subjects: 199
Study 19462434 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Calprotectin and Tumor M2-PK
Number of subjects: 199
Study 19462434 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Calprotectin or Tumor M2-PK
Number of subjects: 199